Quigley Applauds Implementation of ACT for ALS

Today, U.S. Representative Mike Quigley (IL-05) applauded the announcement by the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) of the implementation of his legislation, ACT for ALS, which was signed into law by President Joe Biden last year. The agencies announced the launch of a public-private partnership aimed at advancing the understanding of neurodegenerative diseases and fostering the development of treatments for amyotrophic lateral sclerosis (ALS) and other rare neurodegenerative diseases, as required by Section 3 of Quigley's ACT for ALS.

Quigley released the following statement in response to this encouraging development:

"ALS patients have spent years advocating for change and for a chance to live full, healthy lives. With this announcement, NIH and FDA have taken a major step to accelerate our understanding of this disease. Now, the people living with ALS and their families who fought so hard to pass ACT for ALS into law can celebrate this step in the journey to end ALS and ensure the next generation of patients are not met with the same burden they have endured. This disease is a death sentence, but the ALS community has never given up hope. I will continue to stay active in this effort and see to it that one day, we will have ended ALS and other neurodegenerative diseases once and for all."

The ACT for ALS was signed into law on December 23, 2021, by President Biden and requires HHS, through FDA and NIH, to establish a public-private partnership to advance the understanding of neurodegenerative diseases and foster the development of new treatments no later than one year after enactment.